Cargando…
Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, ito...
Autores principales: | Budamakuntla, Leelavathy, Shree-Lakshmi, HV, Bansal, Akshi, Venkatarayaraju, Shankar Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501705/ https://www.ncbi.nlm.nih.gov/pubmed/31119094 http://dx.doi.org/10.2147/PTT.S154073 |
Ejemplares similares
-
Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017) -
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
por: Pai, Ganesh, et al.
Publicado: (2017) -
A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis
por: Parthasaradhi, Anchala, et al.
Publicado: (2017) -
Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]
Publicado: (2015) -
Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis
por: Menon, Roshni, et al.
Publicado: (2015)